BioNano Genomics (2Y3) Q2 2026 Earnings Report

The call conveyed strong execution on key commercial and clinical fronts: double-digit revenue growth, record flow-cell sales, a shift to higher-margin consumable revenue, improved gross margins (53%), significant clinical publications validating OGM, and the retirement of convertible debt. These positives were tempered by operational constraints — notably manufacturing capacity and backorders — a modest cash balance with runway into early 2027, and a YoY decline in software revenue. Management raised the low end of full-year guidance but remained cautious on the upside until supply constraints are resolved.

Bionano raised the low end of its full‑year 2026 revenue guidance to $31.0M–$33.0M (up ~9%–16% vs. 2025) and initiated Q3 guidance of $8.2M–$8.6M (up ~11%–16% vs. Q3 2025) after reporting Q2 revenue of $8.2M (up 21% YoY and above prior guidance of $7.5M–$7.8M), selling 9.22k flow cells (up 27% YoY), delivering a record adjusted gross margin of 53%, recording adjusted operating expense of $8.7M, ending the quarter with $10.4M in cash/short‑term securities (including $0.5M restricted) and a cash runway into at least Q1 2027, and noting full retirement of its senior secured convertible debt — while management cautioned they kept the upside conservative due to flow‑cell manufacturing constraints, backlog and several large orders that could slip.